At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 270 enrolled
Drug / intervention
Mavenclad®drug
Likely dose
Mavenclad® 3.5 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
In Brief
A Phase 4 clinical trial evaluating Mavenclad® for Multiple Sclerosis. Completed, enrolled 270 participants across 54 sites in 14 countries.
Detailed Summary
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAustralia, Austria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartMay 2018
Primary CompletionMay 2020
Study CompletionFeb 2022
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartMay 28, 2018
Primary CompletionMay 5, 2020
Study CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.6 years ago
Interventions
Mavenclad®drug
Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.